S-E. Al-Batran

724 total citations
21 papers, 487 citations indexed

About

S-E. Al-Batran is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, S-E. Al-Batran has authored 21 papers receiving a total of 487 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 7 papers in Surgery. Recurrent topics in S-E. Al-Batran's work include Gastric Cancer Management and Outcomes (16 papers), Colorectal Cancer Treatments and Studies (9 papers) and Esophageal Cancer Research and Treatment (6 papers). S-E. Al-Batran is often cited by papers focused on Gastric Cancer Management and Outcomes (16 papers), Colorectal Cancer Treatments and Studies (9 papers) and Esophageal Cancer Research and Treatment (6 papers). S-E. Al-Batran collaborates with scholars based in Germany, United States and Switzerland. S-E. Al-Batran's co-authors include Claudia Pauligk, Sylvie Lorenzen, Elke Jäger, Nils Homann, Harald Schmalenberg, Florian Lordick, Martin Schüler, Peter Thuss‐Patience, J.W. Park and Daniel Maurus and has published in prestigious journals such as SHILAP Revista de lepidopterología, British Journal of Cancer and Annals of Oncology.

In The Last Decade

S-E. Al-Batran

18 papers receiving 478 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S-E. Al-Batran Germany	10	302	220	179	77	75	21	487
Andriy Rusyn Ukraine	9	212 0.7×	285 1.3×	108 0.6×	61 0.8×	108 1.4×	16	485
Izuma Nakayama Japan	14	450 1.5×	527 2.4×	214 1.2×	103 1.3×	46 0.6×	108	820
S-E. Al-Batran Germany	12	326 1.1×	380 1.7×	175 1.0×	158 2.1×	10 0.1×	55	711
Prabhsimranjot Singh United States	8	141 0.5×	117 0.5×	50 0.3×	11 0.1×	55 0.7×	26	325
Keun-Wook Lee South Korea	7	379 1.3×	409 1.9×	148 0.8×	108 1.4×	5 0.1×	13	585
Feng-yi Feng China	8	345 1.1×	450 2.0×	129 0.7×	90 1.2×	5 0.1×	35	673
Hidekazu Hirano Japan	12	225 0.7×	368 1.7×	158 0.9×	66 0.9×	3 0.0×	91	586
Annika Ålgars Finland	14	161 0.5×	393 1.8×	122 0.7×	33 0.4×	5 0.1×	34	657
Shoichi Dowaki Japan	13	163 0.5×	345 1.6×	361 2.0×	20 0.3×	4 0.1×	36	710
Amadeu Pimenta Portugal	13	276 0.9×	126 0.6×	233 1.3×	138 1.8×	3 0.0×	19	454

Countries citing papers authored by S-E. Al-Batran

Since Specialization

Citations

This map shows the geographic impact of S-E. Al-Batran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S-E. Al-Batran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S-E. Al-Batran more than expected).

Fields of papers citing papers by S-E. Al-Batran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S-E. Al-Batran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S-E. Al-Batran. The network helps show where S-E. Al-Batran may publish in the future.

Co-authorship network of co-authors of S-E. Al-Batran

This figure shows the co-authorship network connecting the top 25 collaborators of S-E. Al-Batran. A scholar is included among the top collaborators of S-E. Al-Batran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S-E. Al-Batran. S-E. Al-Batran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hacker, Ulrich, et al.. (2024). SAGA—a phase Ib/II single-arm, multicenter study of sacituzumab govitecan for patients with metastatic esophagogastric adenocarcinoma. SHILAP Revista de lepidopterología. 4. 100051–100051. 5 indexed citations

Al-Batran, S-E., Sylvie Lorenzen, Nils Homann, et al.. (2021). 1429P Pathological regression in patients with microsatellite instability (MSI) receiving perioperative atezolizumab in combination with FLOT vs. FLOT alone for resectable esophagogastric adenocarcinoma: Results from the DANTE trial of the German Gastric Group at the AIO and SAKK. Annals of Oncology. 32. S1069–S1069. 22 indexed citations

Al-Batran, S-E., Ralf‐Dieter Hofheinz, Harald Schmalenberg, et al.. (2020). 1424MO Perioperative FLOT plus ramucirumab versus FLOT alone for resectable esophagogastric adenocarcinoma– Updated results and subgroup analyses of the randomized phase II/III trial RAMSES/FLOT7 of the German AIO and Italian GOIM. Annals of Oncology. 31. S901–S901. 5 indexed citations

Al-Batran, S-E., Tobias Dechow, Eray Goekkurt, et al.. (2020). 1499TiP FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for taxane-pretreated patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy – The phase II/III RAMIRIS study. Annals of Oncology. 31. S930–S930.

Thuss‐Patience, Peter, S-E. Al-Batran, Claudia Pauligk, et al.. (2020). 1495P FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – Final results from the phase II RAMIRIS Study of the AIO. Annals of Oncology. 31. S928–S928. 3 indexed citations

Lorenzen, Sylvie, Claudia Pauligk, Rolf Mahlberg, et al.. (2020). 1502TiP Paclitaxel + ramucirumab versus paclitaxel alone in patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs - RAMOS, a randomized phase II trial of the German Gastric Group of the AIO. Annals of Oncology. 31. S931–S931.

Shitara, Kohei, S-E. Al-Batran, Y-J. Bang, et al.. (2020). 198TiP SPOTLIGHT: Phase III study of zolbetuximab + mFOLFOX6 versus placebo + mFOLFOX6 in first-line Claudin18.2⁺/HER2⁻ advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ). Annals of Oncology. 31. S1317–S1317. 9 indexed citations

Ajani, Jaffer A., S-E. Al-Batran, Y-J. Bang, et al.. (2020). 195TiP GLOW: Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin18.2⁺/HER2⁻ advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ). Annals of Oncology. 31. S1315–S1316. 5 indexed citations

Türeci, Ö., Uğur Şahin, Henning Schulze‐Bergkamen, et al.. (2019). A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Annals of Oncology. 30(9). 1487–1495. 161 indexed citations

10.

Goekkurt, Eray, Mascha Binder, Sylvie Lorenzen, et al.. (2018). Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): The randomized phase II INTEGA trial (AIO STO 0217). Annals of Oncology. 29. viii265–viii266.

11.

Al-Batran, S-E., Claudia Pauligk, Nils Homann, et al.. (2017). Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer: Updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO). Annals of Oncology. 28. v616–v616. 16 indexed citations

12.

Lordick, Florian, Martin Schüler, S-E. Al-Batran, et al.. (2016). 220O Claudin 18.2 - a novel treatment target in the multicenter, randomized, phase II FAST study, a trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as 1st line therapy in advanced gastric and gastroesophageal junction (GEJ) cancer. Annals of Oncology. 27. ix69–ix69. 2 indexed citations

13.

Al-Batran, S-E., Wael Hozaeel, Ralf‐Dieter Hofheinz, et al.. (2015). The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax). Annals of Oncology. 26(6). 1244–1248. 46 indexed citations

14.

Trarbach, Tanja, Martin Schüler, Zanete Zvirbule, et al.. (2014). Efficacy and Safety of Multiple Doses of Imab362 in Patients with Advanced Gastro-Esophageal Cancer: Results of a Phase Ii Study. Annals of Oncology. 25. iv218–iv218. 14 indexed citations

15.

Cunningham, David, S-E. Al-Batran, Ірина Давиденко, et al.. (2014). Rilomet-1: an International Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Trial of Rilotumumab Plus Epirubicin, Cisplatin and Capecitabine (Ecx) As First Line Therapy in Patients with Advanced Met-Positive Gastric or Gastroesophageal Junction (G/Gej) Adenocarcinoma. Annals of Oncology. 25. iv250–iv250. 8 indexed citations

16.

Quidde, Julia, Dirk Arnold, S. Hegewisch-Becker, et al.. (2014). Quality of Life (Qol) in Patients with Metastatic Colorectal Cancer (Mcrc) Receiving Maintenance Therapy After First-Line Inductive Treatment: a Qol Sub-Analysis of the Aio Krk 0207 Phase III Trial. Annals of Oncology. 25. iv177–iv177. 1 indexed citations

17.

Atmaca, Akin, S-E. Al-Batran, Dominique Werner, et al.. (2013). A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer. British Journal of Cancer. 108(2). 265–270. 27 indexed citations

18.

Lorenzen, Sylvie, Claudia Pauligk, Nils Homann, et al.. (2013). Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer. British Journal of Cancer. 108(3). 519–526. 85 indexed citations

19.

Wimberger, Pauline, Hélène Gilet, M. M. Heiss, et al.. (2012). Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone. Annals of Oncology. 23(8). 1979–1985. 54 indexed citations

20.

Al-Batran, S-E., Claudia Pauligk, Michael Scholz, et al.. (2010). Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials. British Journal of Cancer. 103(10). 1518–1523. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact